Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Regulatory
  • Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
  • Regulatory

Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry

BioSpace

The FDA approved Eli Lilly's orforglipron--to be known as Foundayo--on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk's oral Wegovy.

RegulatoryMetabolic & GLP-1Read full story

pharminent April 1, 2026 (Last updated: April 1, 2026)

BioSpace

The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

Previous: FDA Approves First New Molecular Entity Under National Priority Voucher Program
Next: Lilly bags FDA okay for Wegovy pill rival orforglipron

Related Stories

  • Regulatory

Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval

pharminent September 14, 2026
  • Regulatory

Psychedelic therapies ride wave of public favor into FDA hearing

pharminent September 14, 2026
  • Regulatory

Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion

pharminent September 10, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.